Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TNGX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Pan-RAS Molecular Glue ERAS-0015 | PDAC | Phase 1/2 · NCT07897734 | Not yet recruiting |
| Nab-paclitaxel | PDAC | Phase 1/2 · NCT06922591 | Recruiting |
| mFOLFIRINOX | PDAC | Phase 1/2 · NCT06922591 | Recruiting |
| Daraxonrasib (RMC-6236) | PDAC | Phase 1/2 · NCT06922591 | Recruiting |
| Zoldonrasib (RMC-9805) | PDAC | Phase 1/2 · NCT06922591 | Recruiting |
| MAT2A Inhibitor S-095035 | MTAP-deleted Solid Tumors | Phase 1/2 · NCT06188702 | Active not recruiting |
| CoREST Inhibitor TNG260 | Non Small Cell Lung Cancer | Phase 1/2 · NCT05887492 | Active not recruiting |
| USP1 Inhibitor TNG348 | Breast Cancer | Phase 1/2 · NCT06065059 | Terminated |
| PRMT5 Inhibitor TNG456 | Non Small Cell Lung Cancer | Phase 1/2 · NCT06810544 | Recruiting |
| Vopimetostat (TNG462) | Locally Advanced Solid Tumor | Phase 1/2 · NCT05732831 | Recruiting |
| Ralometostat (TNG908) | Locally Advanced Solid Tumor | Phase 1/2 · NCT05275478 | Terminated |
Also used in these trials (approved or third-party drugs, not TNGX's own candidates): Abemaciclib, Olaparib, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TNGX holds $977.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $38M/quarter from operations, an estimated runway of 77.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 39 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TNGX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 25,286,624 | 14.92% | 2026-10-30 |
| Farallon Capital Management, L.L.C. | Institution (13G, 5%+) | 16,270,187 | 9.60% | 2026-06-30 |
| Third Rock Ventures IV, L.P. 10% owner |
Insider | 13,386,574 | 7.90% | 2025-10-23 |
| RTW Investments, LP | Institution (13G, 5%+) | 13,300,620 | 7.85% | 2026-03-31 |
| Dapice Joshua J. | 5%+ holder (13G) | 11,257,203 | 6.64% | 2026-03-31 |
| Davis Aaron I. | 5%+ holder (13D) | 10,740,385 | 6.34% | 2024-12-30 |
| TCG Crossover GP II, LLC | 5%+ holder (13G) | 10,147,867 | 5.99% | 2026-06-30 |
| THE GOLDMAN SACHS GROUP, INC. | Institution (13G, 5%+) | 9,742,403 | 5.75% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 8,477,165 | 5.00% | 2025-12-31 |
| Barbara Weber Director, Executive Chair, Director · +222,132 options |
Insider | 1,629,254 | 0.96% | 2026-02-02 |
| Malte Peters President & CEO, Director · +1.84M options |
Insider | 367,500 | 0.22% | 2026-01-08 |
| Daniella Beckman Chief Financial Officer · +265,980 options |
Insider | 184,297 | 0.11% | 2026-02-02 |
Share count 169,455,160 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TNGX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →